Efficacité et taux de maintenance du liraglutide chez les patients diabétiques de type 2 en pratique clinique courante en France Étude EVIDENCE : Une étude observationnelle, prospective, post-commercialisation, avec un suivi de 2 ans

We report the results of an observational study (EVIDENCE) including 3152 adults with type 2 diabetes who had recently started liraglutide treatment. After 2 years of follow-up, 29.5% of patients maintained liraglutide treatment and reached the HbA1C target < 7, 0%. Mean HbA1C, fasting plasma glucose concentration, and body weight, were significantly reduced from baseline at the end of the study. The main adverse event type was gastrointestinal and the percentage of patients suffering ≥ 1 hypoglycemic episode decreased.